Epithalon

A longevity-circuit celebrity. Cell and animal telomere/pineal findings exist; they have not been converted into rigorous, replicated human outcome trials. 'Adds years' is marketing, not a result.

A tetrapeptide associated with the Khavinson pineal-peptide line. Claims include telomerase activation in cultured cells and pineal/melatonin-axis effects. In vivo human geroprotective proof is not at contemporary trial standard.

Khavinson's group published telomerase and gerontology papers over decades. Independent replication is limited, sample sizes are small, and endpoints are often biomarkers rather than hard clinical events. Interesting biochemistry, thin clinical inference.

Not FDA-approved. Research chemical. Pineal peptide extracts (epithalamin) were used in some post-Soviet clinical settings; that is not a US approval.

Not approved. July 2026 PCAC recommended 503A listing for Epitalon-related bulk substances (non-binding). No US pharmacy product. Research-chemical tetrapeptide sales are the unofficial market.

Same four pathways as the Sourcing guide.

None.

Longevity-forum staple, often stacked with other 'geroprotectors.' Khavinson-era pineal extracts are not the same as a US-compounded AEDG vial, and neither is an approved drug.

Strand does not list vendors. See the grey market.

Short-sequence peptides can still be bioactive. Unregulated injectables carry the usual sterility risk. Telomerase-activation hypotheses deserve a cancer-biology pause, even if human exposure data are sparse.

• Telomerase-activation hypotheses deserve a cancer-biology pause.
• Human outcome RCTs at contemporary standard are lacking.
• Unregulated injectables carry sterility risk.

• Khavinson et al. · 2014 · Bull Exp Biol Med

  Peptide regulation of gene expression and telomerase activity (AEDG). PMID 25403401.

• Evidence standard

  Lacks contemporary, independently replicated outcome RCTs.